Now approved: Sustiva in combination offers patients a new first-line therapy.
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017277:Drug Approval; D004359:Drug Therapy, Combination; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000627:therapeutic use*; D006801:Humans; D010078:Oxazines / Q000627:therapeutic use*; D014486:United States Food and Drug Administration
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D017320:HIV Protease Inhibitors; D010078:Oxazines; C098320:efavirenz